Shilpa Medicare Ltd. has successfully received Good Manufacturing Practice (GMP) approval from the Ministry of Health, Belarus, for its Unit IV in Jadcherla and Unit VII in Nacharam, Hyderabad. This certification, granted in October 2024, is recognized across the Eurasian Economic Union (EEU) countries, including Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia.
Unit IV specializes in manufacturing, testing, and distributing sterile injectable and non-sterile oral dosage forms for global markets, including the US and Europe. Unit VII focuses on testing raw materials, packing materials, and finished dosage forms.
This GMP approval opens significant business opportunities for Shilpa Medicare in EEU member countries, strengthening its position in the international pharmaceutical market.
I the meantime, Shilpa Medicare shares opened at ₹770.00 today, with a high of ₹779.00 and a low of ₹759.50. The stock has seen a significant range over the past 52 weeks, reaching a high of ₹959.50 and a low of ₹313.15.
